Granted, the average life scientist probably isn't going to learn sparql to get an answer to his or her question, but that simply begs another question, why don't we have better open source told for querying rdf and visualizing the results?
chem-bla-ics: Linked Open Drug Data: three years on.
During this hackathon we will work on projects relating to any of the major challenges of biomedical big data, including:
Locating, gaining access to, standardizing, and documenting data, software tools, and APIs Developing effective, robust, reproducible and interoperable means of sharing data and software tools
Developing new methods for analysing biomedical big data
Training researchers for analysing biomedical big data
For more information see: https://github.com/Network-of-BioThings/nob-hq/wiki/1st-BD2K-3rd-Network-of-BioThings-Hackathon
Register Here: https://www.eventbrite.com/e/bd2k-hackathon-tsri-tickets-16010420599
Add a project idea to the list of projects: https://docs.google.com/document/d/1AEzaMaH1NPBIS9Jg7xVPXbnAs4jlCXbmUk-eUAYkb4k/edit?usp=sharing
We have several scholarships and travel awards available. Please fill out this form to be considered. https://docs.google.com/forms/d/13GqTQ4u43MZSnkaFyXhpg7wO12d-LqH5WgHFxq-1p-o/viewform
Looking forward to seeing you!
chem-bla-ics: Programming in the Life Sciences #21: 2014 Screenshots #1.
- Texas A&MComputer Science, 1983 - 1988
- Aspen BiosciencesPrincipal Consultant, 2009 - present
- GenometrixSr. Software Engineer, 1999 - 2001
- Lexicon GeneticsMgr Bioinformatics, 2001 - 2005
- PfizerSr. Analyst, 2006 - 2007
- L-3 CommuncationsSr. Software Engineer, 2007 - 2008
- Takeda PharmaceuticalsSr. Software Engineer, 2008 - 2009
- Shell Services InternationalConsultant, 1997 - 1999
- University of HoustonSr. Bioinformatics Software Engineer, 2005 - 2006
- Landmark GraphicsMarketing Technologist, 1994 - 1997
Solar Activity At Birth Could Influence Our Lifespan | IFLScience
While astrology is still a load of rubbish, it turns out that your future could actually be written in the stars after all. Well, star.
Bert Vogelstein’s Liquid Biopsy Blood Test for DNA Could Stop Cancer | M...
He watched his brother die from a cancer that no drug could cure. Now one of the world’s most renowned cancer researchers says it’s time for
New features simplify access to annotation information in NCBI's Gene
NCBI NCBI Logo; Skip to main content; Skip to navigation; Resources · All Resources; Chemicals & Bioassays. BioSystems · PubChem BioAssay ·
Techniques for faster discovery and isolation of human monoclonal antibodies
Increased funding raises hopes in pancreatic cancer research
An uptick in funding for pancreatic cancer research is finally giving scientists some hope that they'll be able to tackle this baffling and
New Cancer Drugs Make Tumors Drug Resistant, More Aggressive
A popular cancer treatment makes cancer worse, but researchers believe they've found a remedy for that.
National Cancer Institute investigating trial outliers to resurrect 'fai...
After sifting through 10 years' worth of clinical trial data, NCI's Cancer Diagnosis Program says the program has identified about 100 "exce
Party drug turned 'miracle' cure for depression spurs hype and stubborn ...
The notion that a party drug could be repurposed into a "miracle" cure for severe, treatment-resistant depression is an almost irresistible
Celgene pays VCs $47M to up its stake in Acceleron's pipeline
The dealmakers at Celgene like to get really, really close to their biotech partners. And nothing demonstrates the sincerity of their intere
Halozyme tanks after another mid-stage setback dings its cancer drug
Halozyme has pressed pause on a Phase II trial of its lead cancer candidate over safety concerns, news that sent the biotech's shares down 2
UPDATED: Pfizer's flagship palbociclib stymies cancer progression but fa...
In the first detailed glimpse of palbociclib's impact on overall survival--a key feature to the future prospects of this flagship program--t
Little Deciphera raises its cancer R&D flag in Boston's bustling...
It's not often you find a little biotech company plugging away at new cancer drugs in out-of-the-way places like Lawrence, KS. But that's ju
Puma surges as neratinib beats Herceptin in head-to-head breast cancer s...
Puma Biotechnology is boasting that its experimental cancer drug neratinib bested Herceptin in a head-to-head study of HER2-positive breast
Lilly preps a PhIII study as breast cancer drug race heats up
One of the big surprises at the annual meeting of the American Association for Cancer Research last weekend belonged to none other than Eli
Challenges for drug development jsr slides aug 2013
MEETING THE CHALLENGES FOR DRUG DEVELOPMENT IN THE 21st CENTURY Jan S. Rosenbaum, Ph.D. CincyTech